Economic availability of medicinal products, which affect on structure and mineralization of bones on the pharmaceutical market of Ukraine
In recent decades, the problem of osteoporosis has become acute for Ukraine in connection with two demographic processes: a sharp increase in the population of the elderly and senile age and, correspondingly, the number of women in postmenopausal women. At present, the share of the population of Ukraine at the age of 60 years and older is 23.1% (men – 18.1%, women – 27.3%). The number of patients with osteoporosis and its complications is increasing. In connection with this, an analysis of the assortment of medicines affecting the structure and mineralization of bones (bisphosphonates) was carried out.
The analysis was conducted during 2014–2016 according to the analytical system of research of the pharmaceutical market «RharmExplorer». For the analysis of socio-economic accessibility of bisphosphonates, an indicator of adequacy of solvency was calculated.
In the analysis of the pharmaceutical market in Ukraine the period from 2014 to 2016, 10 INN were installed. In 2014, the market of Ukraine was represented by 41 TN, of which 9 TN of domestic production and 32 TN of foreign production. In 2015, there are 44 TNs, of which 11 TN of domestic production and 33 TN of foreign production. In 2016, there are 40 TNs, of which 12TN of domestic production and 28 TN of foreign production.
The obtained data testify that preparations influencing the structure and mineralization of bones are represented on the market in a wide range. During the study period 2014–2016, there were 10 INN drugs on the market, on the basis of which 41, 44 and 40 TNs were represented by years respectively. Analysis of economic accessibility of bisphosphonates showed that the vast majority of them for a course of treatment for 1 month is available for all categories of the population. Only preparations based on zoledronic acid and denzomab are not readily available to the public. In 2016, 100% of alendron acid preparations and 50% of risedron acid preparations were classified as highly available preparations.
2. Alekseeva L. Y. Alendronat v lechenyy osteoporoza // Consilium medicum. – 2012. – T. 14, № 2. – S. 71–75
3. Belovol A. N., Knyaz'kova I. I. Bisfosfonaty v lechenii osteoporoza // Klin. farmakologiya i terapiya. – 2014. – № 23 (5). – S. 75–79.
4. Rizzoli R. Atlas of postmenopausal osteoporosis. – Current Medicine Group, 2005. – P. 25–90.
5. Zotkin Ye. G., Khurtsilava O. G., Safonova Yu. A. Priverzhennost' patsiyentov s osteoporozom terapii bisfosfonatami // Effektivnaya farmakoterapiya. Spetsvypusk «Osteoporoz». – 2012. – S. 26–32.
6. Shvarts G. Ya. Farmakoterapiya osteoporoza. – M.: MIA, 2002. – S. 57–72.
7. Prohramnyy kompleks «Apteka» kompaniyi «Morion» [Elektronnyy resurs]. – Rezhym dostupu: NTT: //pharmbase.com.ua/poisk/
8. Herasymova O. O., Krasyuk A. A. Analiz asortymentu ta dostupnosti likars'kykh zasobiv, shcho vykorystovuyut'sya v skhemakh antykhelikobakternoyi terapiyi, na farmatsevtychnomu rynku Ukrayiny // Upravlinnya, ekonomika ta zabezpechennya yakosti v farmatsiyi. – 2017. – № 2 (50). – S. 54–62.
9. Shina Y., Engebretsen L., Iwasa J. et al. Use of bisphosphonates for the treatment of stress fractures in athletes // Knee Surg. Sports Traumatol. Arthrosc. – 2011. – N 17 (5). — P. 542–550.
10. Povoroznyuk V. V., Dzerovich N. I., Karasevskaya T. A. Bone mineral density in Ukrainian women of different age // Ann. N. Y. Acad. Sci. – 2007. – V. 1119. – P. 243–252.
11. Yarmolinskaya M. I. Postmenopauzal'nyy osteoporoz. Klinika, diagnostika, profilaktika, lecheniye. Uch. posobiye. – M.: Iz-vo «Serebryanyye niti», 2014. – 60 s.
12. Lesnyak O. M., Zakroyeva A. G. Sovremennyye vozmozhnosti medikamentoznogo lecheniya postmenopauzal'nogo osteoporoza i puti resheniya problem komplayentnosti // Lechashchiy vrach. – 2012. – № 7. – S. 94–99.
13. Imaz I., Zegarra P., Gonzalez-Enriquez J. et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis // Osteoporos. Int. – 2010. – V. 21. – P. 1943–1951.
This work is licensed under a Creative Commons Attribution 4.0 International License.